Century Therapeutics (IPSC) Investor Presentation - Slideshow

Company Overview - Century is building a next-generation allogeneic cell therapy platform leveraging iPSC reprogramming, gene editing, and protein engineering[5, 6, 7] - The company has established in-house manufacturing capabilities to accelerate learning and product iteration[8] - Century's platform utilizes precision CRISPR MAD7 mediated sequential gene editing of iPSC cells to generate uniform product candidates[9] - Allo-EvasionTM edits are designed to overcome major pathways of host vs graft rejection, potentially leading to greater durability[13, 14] - The company has a experienced team in R&D, immuno-oncology, manufacturing and commercialization[19] Pipeline and Clinical Development - The company's lead product candidate, CNTY-101, is a differentiated next-generation CD19 targeted iNK cell product[35] - Preclinical data for CNTY-101 shows 62% to 70% tumor growth inhibition (TGI) in lymphoma models[38] - The ELiPSE-1 study, a first-in-human study of CNTY-101, dosed its first patient in February 2023 and is currently enrolling patients with relapsed/refractory CD19+ B-cell lymphomas[39] - CNTY-102 leverages the γδ iT platform and is designed to deliver best-in-class potential[68] - CNTY-107 is a first-in-class Nectin-4 targeted γδ iT cell therapy for solid tumors[62] Financial Position - The company ended 4Q22 with $367.4 million in cash, cash equivalents, and investments, providing a cash runway into 2026[65, 75]